Next Ozempic? Retatrutide's Unknown Skin Effect (Pathologist Explains)
The strongest weight-loss drug ever made is causing a brand-new skin and nerve reaction, and no one has published a biopsy on it yet. As a triple board-certified practicing physician and dermatopathologist, here is what you need to know about the next Ozempic (Retatrutide), dysesthesia, and the hidden dangers of the peptide gray market. 👇 Download the FREE Vial Audit (with ER & Baseline Labs Cards): 🔗 https://draminhedayat.com/vial_audit (Copy Paste the link in your browser in the link doesn't work) 🔬 About This Video Retatrutide is yielding nearly 29% body weight loss in the latest TRIUMPH clinical trials, but up to 1 in 5 users at higher doses are experiencing dysesthesia, a neurocutaneous reaction causing burning, tingling, and extreme skin sensitivity. Alarmingly, thousands of people are bypassing the clinical path, mixing unverified research peptides at home, and stacking them with untested drugs like Tesamorelin. In this forensic breakdown, Dr. Amin Hedayat pulls back the curtain on what happens when your nerves and skin misfire, the reality of "bacteriostatic water" contamination, the severe chain-of-custody risks with online peptide vendors, and the five questions you must ask before injecting anything into your body. 👉 Join the GetUninflamed Waitlist (Opening soon): 🔗 https://GetUninflamed.com ⏱️ Video Chapters 00:00 - The slide nobody looked at 03:34 - The Two Doors 05:03 - Four molecules, one landscape 07:45 - The Chain of Custody 09:19 - What is actually in the vial 11:30 - The Water 14:07 - What the studies really show 15:57 - Dysesthesia, the missing biopsy 17:57 - But I take a low dose 19:52 - The Risks of Tesamorelin and Retrotrutide Stack 21:32 - The Vial Audit: Five Questions to Ask 22:27 - Understanding the Risks of Peptides 23:41 - The Importance of Asking Questions 25:20 - Getuninflamed.com 📺 Watch My Previous Videos on Ozempic & GLP-1s Before diving deep into Retatrutide, make sure you understand the foundational science behind these molecules. Watch these next: How To Stop The Rebound With Ozempic & Mounjaro • How To Stop The Rebound With Ozempic & Mou... I'm a Pathologist: How To Boost GLP-1 Naturally (No Injections) • I’m a Pathologist: How To Boost GLP-1 Natu... I'm a Pathologist. Retatrutide is NOT Ozempic. It's Biological Overdrive. • I’m a Pathologist. Retatrutide is NOT Ozem... I'm a Pathologist. Ozempic & Mounjaro Aren't Actually Weight Loss Drugs. • I'm a Pathologist. Ozempic & Mounjaro Aren... I'm a Pathologist: The "Biological Cost" of Ozempic and Mounjaro • I’m a Pathologist: The "Biological Cost" o... 📚 Scientific References & Medical Literature Retatrutide Phase 2 Trial: Jastreboff AM et al. NEJM 2023;389(6):514-526. https://www.nejm.org/doi/full/10.1056... TRIUMPH-4 (Knee Osteoarthritis, Phase 3): Eli Lilly topline, December 2025. https://investor.lilly.com/news-relea... TRIUMPH-1 (Phase 3 Obesity): Eli Lilly, presented at ADA 2026. https://www.prnewswire.com/news-relea... Tesamorelin Phase 3 Trial: Falutz J et al. NEJM 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/17898... IGF-1 and Cancer Risk: Renehan AG et al. Lancet 2004;363(9418):1346-1353. https://pubmed.ncbi.nlm.nih.gov/15110... FDA Warning Letters to GLP-1 Compounders (September 2025): https://www.fda.gov/inspections-compl... FDA Warning Letter Naming Retatrutide (GLP-1 Solution), September 9, 2025: https://www.fda.gov/inspections-compl... FDA Concerns with Unapproved GLP-1 Drugs: https://www.fda.gov/drugs/postmarket-... Injection-Related Nontuberculous Mycobacterial Infections, Systematic Review 2025: https://pmc.ncbi.nlm.nih.gov/articles... Foundayo (Orforglipron) FDA Approval, April 1, 2026: https://www.accessdata.fda.gov/drugsa... ⚠️ Medical Disclaimer: This video is for educational and informational purposes only. It does not establish a doctor-patient relationship and does not constitute personal medical advice. Any changes to your medications, supplements, or metabolic health strategy should be evaluated and managed directly by your personal treating physician. Dr. Amin Hedayat has zero financial ties, corporate sponsorships, or affiliate connections with any pharmaceutical manufacturers or peptide retailers. #Retatrutide #Ozempic #Peptides #WeightLossDrugs #Dysesthesia #Mounjaro #Zepbound #GrayMarketPeptides #Pathology #DrAminHedayat
